The widely known and most commonly used dosage of acetate is 35 mg to 150 mg every day. There are some athletes who take around 50 mg to 100 mg every day. But they do not take acetate alone instead they add some other steroids like Masteron in order to accomplish perfect effect at the end of the day. If the dosage exceeds 150 mg per day than there can be several anomalies occurring. The stimulation of the nervous system would be raised. If the acetate is used in longer cycles than it can discontinue the production of natural testosterone in the body. This problem is highly rare and users can avoid facing this problem by controlling their steroid cycle properly.
Injectable steroids are injected into muscle tissue, not into the veins. They are slowly released from the muscles into the rest of the body, and may be detectable for months after last use. Injectable steroids can be oil-based or water-based. Injectable anabolic steroids which are oil-based have longer half-life than water-based steroids. Both steroid types have much longer half-lives than oral anabolic steroids. And this is proving to be a drawback for injectables as they have high probability of being detected in drug screening since their clearance times tend to be longer than orals. Athletes resolve this problem by using injectable testosterone early in the cycle then switch to orals when approaching the end of the cycle and drug testing is imminent.
Trenbolone acetate is a modified form of nandrolone.  The structure of trenbolone acetate is a 19-nor classification, which represents a structural change of the testosterone hormone. Trenbolone acetate lacks a carbon atom at the 19 position and carries a double bond at carbons 9 and 11. The position of these carbons slows its metabolism, which greatly increases its binding affinity to the AR, and inhibits it from undergoing aromatization into the corresponding estrogenic metabolite. Trenbolone acetate contains trenbolone modified with the addition of a carboxylic acid ester ( acetic acid ) at the 17β-hydroxyl group.  This facilitates the slow release of the AAS from the area of injection.